SanBio Company Limited (OTCMKTS:SNBIF – Get Free Report) fell 20% during mid-day trading on Tuesday . The stock traded as low as C$4.65 and last traded at C$4.65. 1,827 shares changed hands during mid-day trading, a decline of 23% from the average session volume of 2,364 shares. The stock had previously closed at C$5.81.
SanBio Stock Performance
The business has a 50 day moving average price of C$4.40 and a 200 day moving average price of C$4.04.
About SanBio
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson’s disease, spinal cord injury, and Alzheimer’s disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis.
See Also
- Five stocks we like better than SanBio
- How to Calculate Retirement Income: MarketBeat’s Calculator
- AMD vs. NVIDIA: The Better Semiconductor Bet for 2025
- The How and Why of Investing in Gold Stocks
- 3 Stocks With Rising Prices That Are Likely to Split in 2025
- Using the MarketBeat Stock Split Calculator
- Why Adobe Stock Could Be the Best Dip Buy in Tech Right Now
Receive News & Ratings for SanBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SanBio and related companies with MarketBeat.com's FREE daily email newsletter.
